SCHEMBL6779368

SCHEMBL6779368

Fc1ccc(-c2nnn(-c3ccc(Cl)cc3)c2-c2ccncc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 5/20 0.60
BRAF P15056 5/20 0.60
KDR P35968 5/20 0.60
POLB P06746 1/20 0.51
MAPK14 Q16539 6/20 0.49
MAPK13 O15264 2/20 0.47
MAPK12 P53778 2/20 0.47
MAPK11 Q15759 2/20 0.47
GCGR P47871 1/20 0.47
FLT3 P36888 2/20 0.46
MEN1 O00255 1/20 0.45
NPC1 O15118 1/20 0.45
TP53 P04637 1/20 0.45
RAB9A P51151 1/20 0.45
KMT2A Q03164 1/20 0.45
RIPK2 O43353 1/20 0.43
EGFR P00533 1/20 0.43
TNK2 Q07912 1/20 0.43
PTK6 Q13882 1/20 0.43
MINK1 Q8N4C8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6772178 0.93 MAPK14 (0.54) SRCBRAFKDRMAPK14MAPK13
SCHEMBL6772362 0.86 MAPK14 (0.49) SRCBRAFKDRMAPK14MAPK13
SCHEMBL6768792 0.86 SRC (0.60) SRCBRAFKDRMAPK14MAPK13
SCHEMBL6623278 0.86 SRC (0.58) SRCBRAFKDRMAPK14MAPK13
SCHEMBL28752074 0.83 ALOX5 (0.50) SRCBRAFKDRMAPK14MAPK13
SCHEMBL6773296 0.83 MAPK14 (0.57) SRCBRAFKDRMAPK14MAPK13
SCHEMBL6778842 0.83 MAPK14 (0.46) SRCBRAFKDRMAPK14MAPK13
SCHEMBL6771371 0.83 SRC (0.62) SRCBRAFKDRPOLBMAPK14
SCHEMBL6774561 0.83 MAPK14 (0.63) SRCBRAFKDRMAPK14MAPK13
SCHEMBL6772267 0.81 PTGS2 (0.56) MAPK14MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1505625-A Triazole compounds useful in treating diseases associated with unwanted cytokine activity 2004-06-16 CN claimed
US-6727364-B2 ANTIINFLAMMATORY AGENTS THE PROCTER & GAMBLE COMPANY 2004-04-27 US claimed
US-20030013712-A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity PROCTER & GAMBLE COMPANY, THE 2003-01-16 US claimed
US-6727364-B2 ANTIINFLAMMATORY AGENTS THE PROCTER & GAMBLE COMPANY 2004-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013712-A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity IL4, IL1A, IL2 SRC 1940/4885BRAF 2861/4885KDR 1645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.